ATE366583T1 - Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 - Google Patents
Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407Info
- Publication number
- ATE366583T1 ATE366583T1 AT00904979T AT00904979T ATE366583T1 AT E366583 T1 ATE366583 T1 AT E366583T1 AT 00904979 T AT00904979 T AT 00904979T AT 00904979 T AT00904979 T AT 00904979T AT E366583 T1 ATE366583 T1 AT E366583T1
- Authority
- AT
- Austria
- Prior art keywords
- mycobacterium
- relates
- differentially expressed
- present
- identification
- Prior art date
Links
- 241000186359 Mycobacterium Species 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99101590 | 1999-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366583T1 true ATE366583T1 (de) | 2007-08-15 |
Family
ID=8237440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00904979T ATE366583T1 (de) | 1999-01-29 | 2000-01-28 | Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7772386B1 (de) |
| EP (1) | EP1146889B1 (de) |
| JP (1) | JP2002534994A (de) |
| AT (1) | ATE366583T1 (de) |
| AU (1) | AU2667600A (de) |
| CA (1) | CA2361246C (de) |
| DE (1) | DE60035485T2 (de) |
| DK (1) | DK1146889T3 (de) |
| ES (1) | ES2288842T3 (de) |
| WO (1) | WO2000044392A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2135947A1 (de) * | 2008-06-17 | 2009-12-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antagonisten bakterieller Sequenzen |
| ITRM20100411A1 (it) * | 2010-07-23 | 2012-01-24 | Massimo Amicosante | Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino. |
| US9726667B2 (en) * | 2014-03-07 | 2017-08-08 | Institute For Systems Biology | Point of care assays to detect the status of tuberculosis infection |
| US11679150B2 (en) * | 2020-03-03 | 2023-06-20 | The United States Of America, As Represented By The Secretary Of Agriculture | Mycoplasma bovis vaccine product |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| KR102405798B1 (ko) * | 2020-06-22 | 2022-06-08 | 주식회사 미코라파 | Rv2882c-Rv2005c 융합 단백질을 포함하는 결핵 면역 치료용 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2624759B2 (ja) * | 1988-03-30 | 1997-06-25 | 味の素株式会社 | Ｂｃｇ菌由来のｍｐｂ６４蛋白及びその製造法 |
| FR2752425B1 (fr) * | 1996-08-19 | 1998-11-13 | Pasteur Institut | Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis |
-
2000
- 2000-01-28 ES ES00904979T patent/ES2288842T3/es not_active Expired - Lifetime
- 2000-01-28 CA CA2361246A patent/CA2361246C/en not_active Expired - Lifetime
- 2000-01-28 US US09/890,339 patent/US7772386B1/en not_active Expired - Fee Related
- 2000-01-28 WO PCT/EP2000/000690 patent/WO2000044392A2/en active IP Right Grant
- 2000-01-28 EP EP00904979A patent/EP1146889B1/de not_active Expired - Lifetime
- 2000-01-28 AU AU26676/00A patent/AU2667600A/en not_active Abandoned
- 2000-01-28 AT AT00904979T patent/ATE366583T1/de not_active IP Right Cessation
- 2000-01-28 DK DK00904979T patent/DK1146889T3/da active
- 2000-01-28 DE DE60035485T patent/DE60035485T2/de not_active Expired - Lifetime
- 2000-01-28 JP JP2000595694A patent/JP2002534994A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2361246A1 (en) | 2000-08-03 |
| WO2000044392A3 (en) | 2000-12-07 |
| DE60035485T2 (de) | 2008-03-20 |
| CA2361246C (en) | 2013-04-16 |
| AU2667600A (en) | 2000-08-18 |
| US7772386B1 (en) | 2010-08-10 |
| DK1146889T3 (da) | 2007-10-22 |
| EP1146889B1 (de) | 2007-07-11 |
| DE60035485D1 (de) | 2007-08-23 |
| WO2000044392A2 (en) | 2000-08-03 |
| JP2002534994A (ja) | 2002-10-22 |
| ES2288842T3 (es) | 2008-02-01 |
| EP1146889A2 (de) | 2001-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brandt et al. | New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population | |
| Hanff et al. | Humoral immune response in human syphilis to polypeptides of Treponema pallidum. | |
| JP4283872B2 (ja) | 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用 | |
| ATE440861T1 (de) | Immunisierung gegen chlamydia pneumoniae | |
| BRPI0208301A8 (pt) | vacinas de ácido nucléico para prevenção de infecção por flavivírus | |
| HUP0105379A2 (hu) | Lawsonia intracellularis elleni oltóanyag | |
| FI895050A0 (fi) | Diagnostiska preparat och vaccin foer mykobakterier i folkhaelso-, medicinsk och veterinaermedicinsk praxis. | |
| ITFI920052A1 (it) | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| ATE526994T1 (de) | Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten | |
| Cho et al. | Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus | |
| Hilleman | Immunologic, chemotherapeutic and interferon approaches to control of viral disease | |
| KR100366482B1 (ko) | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법 | |
| EP1219301A1 (de) | Impfstoffe, die hybride Polypeptide mit mindestens zwei verschiedene Allergenen enthalten | |
| ATE366583T1 (de) | Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 | |
| WO2004020609A3 (en) | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection | |
| Chelliah et al. | Potential DNA vaccine for haemorrhagic septiceamia disease | |
| DE68923286D1 (de) | Impfstoffe und testsätze für haemophilus influenzae. | |
| EP2391640B1 (de) | Clostridium-chauvoei-polypeptid, dna, die das polypeptid kodiert, und vakzin, das das polypeptid umfasst | |
| BRPI0412419A (pt) | proteìna de babésia, ácido nucleico, fragmento de cdna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, vacina, método para a preparação de uma vacina, uso de uma proteìna ou um fragmento imunogênico de referida proteìna, e, testes diagnósticos para a detecção de um ácido nucleico associado com, para a detecção de anticorpos contra, e para a detecção de material antigênico de um organismo da famìlia babesiidae | |
| Nassrullah et al. | Cloning, Sequencing and Expression of the Brucella Melitensis Novel Lomr Protein. | |
| DE602005020428D1 (de) | Sequenzen des schnabel- und federkrankheit-virus, zusammensetzungen und impfstoffe und deren verwendung in der therapie, der diagnose und in assays | |
| Asma et al. | Analysis of outer membrane proteins of Pasteurella multocida strains isolated from buffaloes affected with hemorrhagic septicemia | |
| BR102019004148A2 (pt) | Polipeptídeo ligbnid de leptospira spp. para uso como imunobiológico | |
| Ragavendhar et al. | Sequence analysis, 3-dimensional protein modelling and epitope prediction of Oma87 gene originating from Pasteurella multocida isolate of sheep | |
| WO2022208158A1 (es) | Vacunas efectivas para la prevención del botulismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |